-+ 0.00%
-+ 0.00%
-+ 0.00%
Is Vaxcyte (PCVX) Undervalued On Wider Losses And A Softer Share Price?
Share
Listen to the news

Vaxcyte (PCVX) is back in focus after its latest financial update showed a wider net loss for both the third quarter and the first nine months of 2026, which has sharpened attention on its spending pace.

The wider losses have come alongside a softer patch for the share price. Vaxcyte’s stock has eased in the near term, with a 30 day share price return of down 6.2% and a 7 day move slightly lower. However, the year to date share price return of 36.4% and 1 year total shareholder return of 30.2% still point to stronger momentum over a longer horizon. This suggests recent selling likely reflects shifting views on risk and cash burn rather than a simple reversal of interest.

Compare Vaxcyte's recent swings with a curated group of healthcare names that pair science-heavy pipelines with balance sheet strength in our list of solid balance sheet and fundamentals (24 results) to see what else is on the move.

Vaxcyte now trades well below analyst targets after a sharp step up in reported losses. Is that discount a sign of appropriate caution, or has the market pushed too far for a pre-revenue vaccine platform?

Most Popular Narrative: 46% Undervalued

Analysts on Simply Wall St see Vaxcyte’s fair value at about $117.30 per share, compared with the latest close at $63.37. The analyst consensus Narrative on Simply Wall St ties that gap directly to expectations for late stage vaccine programs and future cash generation.

Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use.

Multiple ongoing late stage VAX-31 adult trials and the planned BLA package are aligned with existing FDA frameworks for pneumococcal vaccines. If successful, these programs could support future product approvals and create a path to commercial revenue.

See why 2 investors see Vaxcyte as 46% undervalued.

Result: Fair Value of $117.30 (UNDERVALUED)

Still, Vaxcyte’s story leans heavily on VAX-31 delivering clean Phase 3 outcomes and on rising R&D and manufacturing costs not draining its US$3.0b cash reserve more quickly than planned.

Find out about the key risks to this Vaxcyte narrative.

Another View: Cash Flow Signals A Very Different Fair Value

Analyst targets suggest Vaxcyte could be worth far more than the current $63.37 share price. The SWS DCF model points the other way. On that approach, the estimated future cash flow value sits at $34.29, which frames the stock as expensive rather than undervalued. Which story do you lean toward?

For a closer look at how the cash flow assumptions stack up against the analyst narrative, Look into how the SWS DCF model arrives at its fair value.

PCVX Discounted Cash Flow as at Nov 2026
PCVX Discounted Cash Flow as at Nov 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vaxcyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 32 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages around Vaxcyte’s value and cash profile can feel confusing, so move quickly, check the full breakdown, and weigh both the 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond Vaxcyte?

If Vaxcyte has sharpened your focus on valuation, risk, and balance sheets, use that momentum to scan wider opportunities with a few targeted screens on Simply Wall St.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending